Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK

Diabetes, Obesity and Metabolism

Volumn 18, Issue 12, 2016, Pages 1157-1166

  Bain, S C ^a   Feher, M ^b   Russell Jones, D ^c,d   Khunti, K ^e  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^c ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

cost effectiveness; diabetes complications; glycaemic control; type 2 diabetes

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; HEMOGLOBIN A1C; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

BODY MASS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR; RISK REDUCTION; TIME TO TREATMENT; UNITED KINGDOM; WEIGHT CONTROL; COMPLICATION; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; ENGLAND; GLUCOSE BLOOD LEVEL; METABOLISM; TOTAL QUALITY MANAGEMENT; WEIGHT LOSS PROGRAM;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; ENGLAND; HUMANS; HYPOGLYCEMIC AGENTS; OBESITY; QUALITY IMPROVEMENT; UNITED KINGDOM; WEIGHT REDUCTION PROGRAMS;

EID: 84987618026     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12760     Document Type: Review

References (100)

1. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NICE guideline 28. 2015. Available from URL: https://www.nice.org.uk/guidance/ng28 (Accessed 30 August 2016).
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58:429–442.
3. Group IDFGD. Global guideline for type 2 diabetes. Diabetes Res Clin Pract. 2014;104:1.
4. Group UPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
5. ADVANCE Collaborative Group, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572.
6. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
7. Seshasai SRK, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829.
8. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
10. Hayward RA, Reaven PD, Wiitala WL, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197–2206.
11. Group UPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865.
12. Kearney P, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117–125.
13. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS. BMJ. 1998;38:703–713.
14. Public Health England. Adult obesity and type 2 diabetes. 2014.
15. Carnethon MR, De Chavez PJD, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA. 2012;308:581–590.
16. Logue J, Walker JJ, Leese G, et al. Association between BMI measured within a year after diagnosis of type 2 diabetes and mortality. Diabetes Care. 2013;36:887–893.
17. Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med. 2014;370:233–244.
18. Mulnier H, Seaman H, Raleigh V, Soedamah-Muthu S, Colhoun H, Lawrenson R. Mortality in people with type 2 diabetes in the UK. Diabet Med. 2006;23:516–521.
19. Abdullah A, Peeters A, De Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract. 2010;89:309–319.
20. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic and diastolic blood pressure factors associated with lack of blood pressure control in the community. Hypertension. 2000;36:594–599.
21. Bramlage P, Pittrow D, Wittchen H-U, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens. 2004;17:904–910.
22. Liese AD, Nichols M, Sun X, D'Agostino RB, Haffner SM. Adherence to the DASH diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care. 2009;32:1434–1436.
23. Azadbakht L, Fard NRP, Karimi M, et al. Effects of the dietary approaches to stop hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients a randomized crossover clinical trial. Diabetes Care. 2011;34:55–57.
24. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366:1567–1576.
25. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009;35:518–523.
26. Espeland M. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374–1383.
27. Look AHEAD Research Group, Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes: four year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566.
28. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–154.
29. Yorkshire and Humber Public Health Observatory. Diabetes Key Facts. York, UK: Yorkshire and Humber Public Health Observatory; 2006.
30. Department of Health. Turning the Corner: Improving Diabetes Care. London, UK: Department of Health; 2006.
31. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–862.
32. Quality and Outcomes Framework, Health and Social Care Information Centre, Information Services Division Scotland. Statistics for Wales, Department of Health, Social Services and Public Safety, 2014–2015. Published in 2015.
33. Holden S, Barnett AH, Peters JR, et al. The incidence of type 2 diabetes in the United Kingdom from 1991 to 2010. Diabetes Obes Metab. 2013;15:844–852.
34. Rhodes E, Prosser L, Hoerger TJ, Lieu T, Ludwig D, Laffel L. Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet Med. 2012;29:453–463.
35. Wilmot EG, Leggate M, Khan JN, et al. Type 2 diabetes mellitus and obesity in young adults: the extreme phenotype with early cardiovascular dysfunction. Diabet Med. 2014;31:794–798.
36. Dart AB, Martens PJ, Rigatto C, Brownell MD, Dean HJ, Sellers EA. Earlier onset of complications in youth with type 2 diabetes. Diabetes Care. 2014;37:436–443.
37. Excellence NIfC. CG 87 – type 2 diabetes: the management of type 2 diabetes. 2009. http://www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf. Accessed 30 August 2016.
38. Inzucchi S, Bergenstal R, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577–1596.
39. National Diabetes Audit. Report 1: care processes and treatment targets. 2015.
40. Scottish Diabetes Survey Monitoring Group. Scottish Diabetes Survey 2014. 2014.
41. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412.
42. Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in US diabetes care, 1999–2010. N Engl J Med. 2013;368:1613–1624.
43. Fhärm E, Cederholm J, Eliasson B, Gudbjörnsdottir S, Rolandsson O. Time trends in absolute and modifiable coronary heart disease risk in patients with type 2 diabetes in the Swedish National Diabetes Register (NDR) 2003–2008. Diabet Med. 2012;29:198–206.
44. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011;32:2143–2152.
45. Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries findings from the Guideline Adherence to Enhance Care (GUIDANCE) study. Diabetes Care. 2013;36:2628–2638.
46. National Diabetes Audit. National Diabetes Audit: executive summary 2009–2010. 2010.
47. Stettler C, Allemann S, Jüni P, et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J. 2006;152:27–38.
48. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
49. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34:1481–1486.
50. Turner RC, Cull CA, Frighi V, Holman RR, Group UPDS. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281:2005–2012.
51. Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocr Metab. 2010;95:1566–1574.
52. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310.
53. Mateo J, Gil-Guillén V, Mateo E, Orozco D, Carbayo J, Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract. 2006;60:422–428.
54. Farmer AJ, Rodgers LR, Lonergan M, et al. Adherence to oral glucose-lowering therapies and associations with 1-year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care. 2016;39:258–263.
55. Sabate E. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organisation; 2003.
56. Currie CJ, Peyrot M, Morgan CL, et al. The impact of treatment noncompliance on mortality in people with type 2 diabetes. Diabetes Care. 2012;35:1279–1284.
57. Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin. 2012;28:969–977.
58. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
59. Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care. 2007;30:807–812.
60. Farmer A, Kinmonth AL, Sutton S. Measuring beliefs about taking hypoglycaemic medication among people with type 2 diabetes. Diabet Med. 2006;23:265–270.
61. Feher M, Vega-Hernandez G, Ye Q, Bogelund M. Potential barriers to insulin intensification in patients with type 2 diabetes in the UK. Diabet Med. 2016;33:155.
62. Dilla T, Costi M, Boye K, et al. The impact of obesity in the management and evolution of diabetes mellitus. Rev Clin Esp. 2008;208:437–443.
63. Blak B, Rigney U, Sternhufvud C, Davis J, Hammar N. Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class. Int J Clin Pract. 2016;70:45–55.
64. Wilding JPH, Bailey CJ, Rigney U, Blak B, Beekman W, Emmas CE. Changes in HbA1c and Weight in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Routine UK Primary Care. Stockholm, Sweden: European Association for the Study of Diabetes; 2015.
65. Horton ES, Silberman C, Davis KL, Berria R. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database. Diabetes Care. 2010;33:1759–1765.
66. Gary TL, Genkinger JM, Guallar E, Peyrot M, Brancati FL. Meta-analysis of randomized educational and behavioral interventions in type 2 diabetes. Diabetes Educ. 2003;29:488–501.
67. Deakin T, Cade J, Williams R, Greenwood D. Structured patient education: the Diabetes X-PERT Programme makes a difference. Diabetic Med. 2006;23:944–954.
68. Khunti K, Gray LJ, Skinner T, et al. Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care. BMJ. 2012;344:e2333.
69. Pringle M, Stewart-Evans C, Coupland C, Williams I, Allison S, Sterland J. Influences on control in diabetes mellitus: patient, doctor, practice, or delivery of care? BMJ. 1993;306:630–634.
70. Wallace T, Matthews D. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM. 2000;93:369–374.
71. Khunti K, Wolden ML, Thorsted BL, Andersen M, Davies MJ. Clinical inertia in people with type 2 diabetes a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36:3411–3417.
72. Calvert MJ, McManus RJ, Freemantle N. Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. Br J Gen Pract. 2007;57:455–460.
73. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14:1–10.
74. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135:825–834.
75. Perlin JB, Pogach LM. Improving the outcomes of metabolic conditions: managing momentum to overcome clinical inertia. Ann Intern Med. 2006;144:525–527.
76. Drass J, Kell S, Osborn M, et al. Diabetes care for medicare beneficiaries: attitudes and behaviors of primary care physicians. Diabetes Care. 1998;21:1282–1287.
77. Safford MM, Shewchuk R, Qu H, et al. Reasons for not intensifying medications: differentiating “clinical inertia” from appropriate care. J Gen Intern Med. 2007;22:1648–1655.
78. Henriksen K, Battles JB, Marks ES, et al. Clinical inertia and outpatient medical errors. Adv Patient Saf. 2005;2:293–308.
79. O'Connor PJ. Improving diabetes care by combating clinical inertia. Health Serv Res. 2005;40:1854–1861.
80. Zafar A, Davies M, Azhar A, Khunti K. Clinical inertia in management of T2DM. Prim Care Diabetes. 2010;4:203–207.
81. Khunti K, Gadsby R, Millett C, Majeed A, Davies M. Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the quality and outcomes framework for diabetes. Diabetic Med. 2007;24:1436–1441.
82. Vaghela P, Ashworth M, Schofield P, Gulliford MC. Population intermediate outcomes of diabetes under pay-for-performance incentives in England from 2004 to 2008. Diabetes Care. 2009;32:427–429.
83. O'Hare JP, Miller-Jones D, Hanif W, et al. The new NICE guidelines for type 2 diabetes–a critical analysis. Br J Diabetes. 2015;15:3–7.
84. Miller CD, Ziemer DC, Kolm P, et al. Use of a glucose algorithm to direct diabetes therapy improves A1C outcomes and defines an approach to assess provider behavior. Diabetes Educ. 2006;32:533–545.
85. Lester WT, Grant RW, Octo Barnett G, Chueh HC. Randomized controlled trial of an informatics-based intervention to increase statin prescription for secondary prevention of coronary disease. J Gen Intern Med. 2006;21:22–29.
86. Handelsman Y, Bloomgarden Z, Grunberger G. American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract. 2015;21:1–87.
87. Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ. What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocr Metab. 2012;97:4605–4612.
88. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154:602–613.
89. Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium–glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013;159:262–274.
90. Stenlöf K, Cefalu W, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372–382.
91. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016;4:411–419.
92. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
93. Gall M-A, Nielsen F, Smidt U, Parving H-H. The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia. 1993;36:1071–1078.
94. Nosadini R, Velussi M, Brocco E, et al. Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate. Diabetes. 2000;49:476–484.
95. Del Prato S, Nauck M, Duran-Garcia S, et al. Durability of dapagliflozin vs. glipizide as add-on therapies in T2DM inadequately controlled on metformin: 4-year data. Diabetologia. 2013;56:S374.
96. Esposito K, Chiodini P, Maiorino MI, Bellastella G, Capuano A, Giugliano D. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials. BMJ Open. 2014;4:e005442.
97. Novo Nordisk rrrrl Top line results: liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results. 2016. Available at URL: https://www.novonordisk.com/bin/getPDF.2020215.pdf. Accessed 30 August 2016.
98. Nyeland M, Ploug U, Richards A, et al. Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care. Int J Clin Pract. 2015;69:281–291.
99. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375:1447–1456.
100. Nathan DM, Buse JB, Kahn SE, et al. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE). Diabetes Care. 2013;36:2254–2261.